AU2003225535A1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer

Info

Publication number
AU2003225535A1
AU2003225535A1 AU2003225535A AU2003225535A AU2003225535A1 AU 2003225535 A1 AU2003225535 A1 AU 2003225535A1 AU 2003225535 A AU2003225535 A AU 2003225535A AU 2003225535 A AU2003225535 A AU 2003225535A AU 2003225535 A1 AU2003225535 A1 AU 2003225535A1
Authority
AU
Australia
Prior art keywords
compositions
methods
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003225535A
Other languages
English (en)
Inventor
John Joseph Hunter
Andrea Lesoon
Eric S. Lightcap
Kyle J. Macbeth
Laura A. Rudolph-Owen
Fong-Ying Tsai
Mark W. Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2003225535A1 publication Critical patent/AU2003225535A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003225535A 2002-01-31 2003-01-30 Methods and compositions for treating cancer Abandoned AU2003225535A1 (en)

Applications Claiming Priority (41)

Application Number Priority Date Filing Date Title
US35360002P 2002-01-31 2002-01-31
US60/353,600 2002-01-31
US36451702P 2002-03-15 2002-03-15
US60/364,517 2002-03-15
US37107502P 2002-04-09 2002-04-09
US60/371,075 2002-04-09
US37150702P 2002-04-10 2002-04-10
US60/371,507 2002-04-10
US37298402P 2002-04-16 2002-04-16
US60/372,984 2002-04-16
US37419402P 2002-04-19 2002-04-19
US60/374,194 2002-04-19
US38299502P 2002-05-24 2002-05-24
US60/382,995 2002-05-24
US38502302P 2002-05-31 2002-05-31
US60/385,023 2002-05-31
US38885302P 2002-06-14 2002-06-14
US60/388,853 2002-06-14
US38939502P 2002-06-17 2002-06-17
US60/389,395 2002-06-17
US39132402P 2002-06-25 2002-06-25
US60/391,324 2002-06-25
US39594402P 2002-07-15 2002-07-15
US60/395,944 2002-07-15
US39772602P 2002-07-22 2002-07-22
US60/397,726 2002-07-22
US40304602P 2002-08-13 2002-08-13
US60/403,046 2002-08-13
US40515502P 2002-08-22 2002-08-22
US60/405,155 2002-08-22
US40636102P 2002-08-27 2002-08-27
US60/406,361 2002-08-27
US42119502P 2002-10-25 2002-10-25
US60/421,195 2002-10-25
US42545602P 2002-11-12 2002-11-12
US60/425,456 2002-11-12
US42762602P 2002-11-19 2002-11-19
US60/427,626 2002-11-19
US43212202P 2002-12-10 2002-12-10
US60/432,122 2002-12-10
PCT/US2003/002588 WO2003065006A2 (en) 2002-01-31 2003-01-30 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
AU2003225535A1 true AU2003225535A1 (en) 2003-09-02

Family

ID=27671411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003225535A Abandoned AU2003225535A1 (en) 2002-01-31 2003-01-30 Methods and compositions for treating cancer

Country Status (5)

Country Link
US (2) US20030157082A1 (enExample)
EP (1) EP1468118A4 (enExample)
JP (1) JP2005522999A (enExample)
AU (1) AU2003225535A1 (enExample)
WO (1) WO2003065006A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537291A (ja) * 2001-05-24 2004-12-16 セフアロン・インコーポレーテツド 新規混合系統キナーゼ（７）（ｍｌｋ７）ポリペプチド、それをコードするポリヌクレオチド、およびそれらの使用方法
WO2002102323A2 (en) 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
US20030153018A1 (en) * 2001-11-27 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
US20030199462A1 (en) * 2002-04-23 2003-10-23 Gabriel Nunez Methods and compositions for regulating cellular signaling
CA2498004C (en) * 2002-09-11 2013-06-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1431399A1 (en) * 2002-12-20 2004-06-23 Clinigenetics Methods and composition for identifying therapeutic agents of atherosclerotic plaque lesions
WO2005103255A1 (en) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formylpeptide receptor (fpr) as a target for anti-malignant glioma therapy
EP2256198A1 (en) * 2004-06-14 2010-12-01 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative and inflammatory diseases
CN101068935B (zh) * 2004-08-10 2012-06-27 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
CA2637988A1 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
JP2010511382A (ja) * 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
EP2188310B1 (en) 2007-08-03 2017-02-08 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
WO2012037553A2 (en) * 2010-09-17 2012-03-22 University Of South Florida Use of pkc-iota inhibitors for the treatment of breast cancer
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) * 2007-10-23 2017-05-25 Biontech Ag Identification of tumor-associated markers for diagnosis and therapy
EP2245066A2 (en) * 2008-01-22 2010-11-03 Biogen Idec MA Inc. Ron antibodies and uses thereof
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US8632982B2 (en) * 2009-05-21 2014-01-21 Institute For Systems Biology Biomarkers for liver injury
WO2010141349A1 (en) * 2009-05-30 2010-12-09 University Of Toledo Soluble guanylyl cyclase a1 and a-8r peptide as diagnostic markers of and therapeutic targets for prostate cancer
US9301991B2 (en) 2009-05-30 2016-04-05 The University Of Toledo sGCalphal inhibiting compositions
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
US20150018294A1 (en) * 2012-02-07 2015-01-15 Arrigo DE BENEDETTI Modulators of tousled kinase in cellular processes
US11058767B2 (en) 2018-02-21 2021-07-13 Bristol-Myers Squibb Company CAMK2D antisense oligonucleotides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
KR20020093017A (ko) * 2000-04-03 2002-12-12 상꾜 가부시키가이샤 포유동물 스핑고신 키나제 유형 2 이성체, 이의 클로닝,발현 및 사용 방법
JP2003532057A (ja) * 2000-04-07 2003-10-28 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内因性の、構成的に活性化される既知ｇタンパク質−共役受容体
EP1578996A4 (en) * 2002-10-18 2007-12-19 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS

Also Published As

Publication number Publication date
US20030157082A1 (en) 2003-08-21
WO2003065006A3 (en) 2004-04-08
EP1468118A2 (en) 2004-10-20
JP2005522999A (ja) 2005-08-04
US20070078088A1 (en) 2007-04-05
WO2003065006A2 (en) 2003-08-07
EP1468118A4 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
AU2003230750A1 (en) Compositions and methods for treating cancer
EP2671581B8 (en) Compositions and methods for treating cancer
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU2003225535A1 (en) Methods and compositions for treating cancer
WO2003073826A8 (en) Novel compositions and methods for cancer
AU2003284242A1 (en) Methods and compositions for use in treating cancer
AU2003291356A1 (en) Methods and compositions for treating cancer using proteasome inhibitors
AU2003226301A1 (en) Method of treating cancer
AU2003243373A1 (en) Cell migration inhibiting compositions and methods and compositions for treating cancer
AU2003256847A1 (en) Method of treating cancer
EP1572118A4 (en) METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
AU2003212894A1 (en) Compositions and methods for treating diarrhea
AU2002364708A1 (en) Novel compositions and methods for cancer
AU2003297573A1 (en) Compositions and methods for treating transplants
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2002308642A1 (en) Methods for treating cancer
AU2003238905A1 (en) Surface treating compositions and methods for using same
AU2003298708A1 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
AU2002337943A1 (en) Novel compositions and methods for cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
EP1587405A4 (en) NEW COMPOSITIONS AND METHODS OF CANCER
AU2003275433A1 (en) Compositions and methods for treating pain
AU2003291730A1 (en) Methods and compositions for treating neurodegenerative diseases
AU2003300171A1 (en) Compositions and methods for treating lung cancer
AU2003295604A1 (en) Gpc15: methods and compositions for treating cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase